ICD-10-CM 2027
ICD-10 code for tumor lysis syndrome NEC
From the official ICD-10-CM alphabetic index entry “Tumor lysis syndrome (following antineoplastic chemotherapy) (spontaneous) NEC”. Page updated September 29, 2026.
About coding tumor lysis syndrome NEC
The ICD-10-CM code for tumor lysis syndrome NEC is E88.3 (Tumor lysis syndrome).
Within E88 (other and unspecified metabolic disorders), E88.3 is specifically for tumor lysis syndrome. Related codes cover disorders of plasma-protein metabolism, not elsewhere classified (E88.0), lipodystrophy, not elsewhere classified (E88.1), Lipomatosis, not elsewhere classified (E88.2), mitochondrial metabolism disorders (E88.4), other specified metabolic disorders (E88.8), metabolic disorder, unspecified (E88.9) and wasting disease (syndrome) due to underlying condition (E88.A).
Use an additional code for adverse effect, if applicable, to identify drug (T45.1X5). Use an additional code for: codes for associated conditions.
As a secondary diagnosis it is an MCC (major complication or comorbidity), which can move an inpatient stay into the highest-paying "with MCC" MS-DRG of its family, unless the principal diagnosis excludes it.
Common questions about tumor lysis syndrome NEC ICD-10 codes
What is the ICD-10 code for tumor lysis syndrome NEC?
- E88.3 — Tumor lysis syndrome.
Is E88.3 billable?
- Yes. E88.3 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can E88.3 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict E88.3 as a principal diagnosis.
Is E88.3 a CC or MCC?
- E88.3 is an MCC (major complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.